Biofrontera AG (B8F.F)
- Previous Close
0.3160 - Open
0.3160 - Bid 0.3160 x 162500
- Ask 0.3480 x 100000
- Day's Range
0.3160 - 0.3160 - 52 Week Range
0.2870 - 1.2000 - Volume
10 - Avg. Volume
674 - Market Cap (intraday)
20.801M - Beta (5Y Monthly) 0.66
- PE Ratio (TTM)
-- - EPS (TTM)
-0.1000 - Earnings Date Apr 22, 2024 - Apr 26, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
5.55
Biofrontera AG, a biopharmaceutical company, engages in the research, development, and marketing of dermatological products. Its products include Ameluz and BF-RhodoLED lamp for the treatment of mild and moderate actinic keratoses on the face and scalp, field cancerization, and fatal squamous cell carcinoma. The company also develops RhodoLED XL for the treatment of multiple interspersed lesions; and Belixos, a medical skin care series for irritated and sensitive skin. It has a collaboration and partnership agreement with Maruho Co., Ltd. The company was founded in 1997 and is headquartered in Leverkusen, Germany.
www.biofrontera.com91
Full Time Employees
December 31
Fiscal Year Ends
Sector
Related News
Performance Overview: B8F.F
Trailing total returns as of 4/19/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: B8F.F
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: B8F.F
Valuation Measures
Market Cap
20.80M
Enterprise Value
18.58M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.72
Price/Book (mrq)
1.45
Enterprise Value/Revenue
0.65
Enterprise Value/EBITDA
-2.61
Financial Highlights
Profitability and Income Statement
Profit Margin
-30.06%
Return on Assets (ttm)
2.38%
Return on Equity (ttm)
-57.22%
Revenue (ttm)
28.63M
Net Income Avi to Common (ttm)
-8.61M
Diluted EPS (ttm)
-0.1000
Balance Sheet and Cash Flow
Total Cash (mrq)
2.1M
Total Debt/Equity (mrq)
8.85%
Levered Free Cash Flow (ttm)
--